Regeneron Pharmaceuticals, Inc. (REGN)
735.20
+0.39
(+0.05%)
USD |
NASDAQ |
Oct 02, 16:00
735.13
-0.07
(-0.01%)
After-Hours: 20:00
Regeneron Pharmaceuticals Price to Book Value : 2.397 for Oct. 2, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 2.397 |
| October 01, 2026 | 2.396 |
| September 30, 2026 | 2.472 |
| September 29, 2026 | 2.447 |
| September 28, 2026 | 2.453 |
| September 25, 2026 | 2.570 |
| September 24, 2026 | 2.596 |
| September 23, 2026 | 2.614 |
| September 22, 2026 | 2.621 |
| September 21, 2026 | 2.603 |
| September 18, 2026 | 2.559 |
| September 17, 2026 | 2.574 |
| September 16, 2026 | 2.526 |
| September 15, 2026 | 2.524 |
| September 14, 2026 | 2.588 |
| September 11, 2026 | 2.548 |
| September 10, 2026 | 2.586 |
| September 09, 2026 | 2.634 |
| September 08, 2026 | 2.642 |
| September 04, 2026 | 2.699 |
| September 03, 2026 | 2.750 |
| September 02, 2026 | 2.778 |
| September 01, 2026 | 2.686 |
| August 31, 2026 | 2.606 |
| August 28, 2026 | 2.590 |
| Date | Value |
|---|---|
| August 27, 2026 | 2.634 |
| August 26, 2026 | 2.657 |
| August 25, 2026 | 2.718 |
| August 24, 2026 | 2.702 |
| August 21, 2026 | 2.720 |
| August 20, 2026 | 2.695 |
| August 19, 2026 | 2.742 |
| August 18, 2026 | 2.642 |
| August 17, 2026 | 2.628 |
| August 14, 2026 | 2.620 |
| August 13, 2026 | 2.628 |
| August 12, 2026 | 2.602 |
| August 11, 2026 | 2.599 |
| August 10, 2026 | 2.635 |
| August 07, 2026 | 2.558 |
| August 06, 2026 | 2.518 |
| August 05, 2026 | 2.506 |
| August 04, 2026 | 2.480 |
| August 03, 2026 | 2.476 |
| July 31, 2026 | 2.487 |
| July 30, 2026 | 2.408 |
| July 29, 2026 | 2.268 |
| July 28, 2026 | 2.267 |
| July 27, 2026 | 2.175 |
| July 24, 2026 | 2.139 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Gilead Sciences, Inc. | 15.18 |
| Alnylam Pharmaceuticals, Inc. | 21.70 |
| Amgen, Inc. | 18.64 |
| Incyte Corp. | 3.652 |
| Vertex Pharmaceuticals, Inc. | 6.315 |
Price to Book Value Related Metrics
| PE Ratio | 18.17 |
| PS Ratio | 5.069 |
| PEG Ratio | 9.300 |
| Price to Free Cash Flow | 22.02 |
| Price | 735.20 |
| Earnings Yield | 5.50% |
| Market Cap | 76.02B |
| PEGY Ratio | 7.395 |
| Operating PE Ratio | 18.87 |
| Normalized PE Ratio | 17.14 |